![Ultimovacs ASA logo](/logos/ULTI.OL.webp)
Ultimovacs ASA
OSE:ULTI.OL
Overview | Financials
Company Name | Ultimovacs ASA |
Symbol | ULTI.OL |
Currency | NOK |
Price | 107.4 |
Market Cap | 3,694,184,100 |
Dividend Yield | 0% |
52-week-range | 67.9 - 178.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Carlos de Sousa |
Website | https://ultimovacs.com |
An error occurred while fetching data.
About Ultimovacs ASA
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD